Cold Chain Technologies (CCT), has reinforced its commitment to expanding its Asia Pacific (APAC) presence with a series of investments and partnerships.
Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies.
Orchestra BioMed Holdings has announced that the company has secured $70 million in new capital from Ligand Pharmaceuticals Incorporated and Medtronic to advance its late-stage partnered cardiology programs.
Centauri, an immunotherapy company, announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound.
Ampersand Capital Partners, a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, has announced the acquisition of CurTec.
One Biosciences has announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.
PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and supported with significant reinvestment by Mubadala Investment Company.
The biotech company, Pila Pharma, is raising 20 million Swedish kronor in an almost fully covered capital raise, which includes a stock option for future use.
OutSee has announced it has secured £1.8M in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.
